89bio, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 102.03 million compared to USD 90.12 million a year ago. Basic loss per share from continuing operations was USD 2.93 compared to USD 4.48 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.77 USD | -5.60% | +8.27% | -21.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.49% | 863M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ETNB Stock
- News 89bio, Inc.
- 89bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022